Skip to main navigation Skip to search Skip to main content

Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma

  • Qian Liang
  • , Lingxin Kong
  • , Xu Zhu*
  • , Yang Du*
  • , Jie Tian*
  • *Corresponding author for this work
  • Chinese Academy of Sciences
  • University of Chinese Academy of Sciences
  • Beijing Key Laboratory of Molecular Imaging
  • Peking University
  • School of Life Science and Technology, Xidian University

Research output: Contribution to journal › Review article › peer-review

Abstract

Morphological imaging techniques are typically used in the anti-cancer drug efficacy evaluation process. However, these techniques can evaluate the therapeutic efficacy only when the tumor shows anatomic changes—usually at later stages, when the therapeutic effects are poor. In contrast, molecular imaging allows noninvasive monitoring of tumor growth, assessment of drug metabolism, and evaluation of therapeutic efficacy at the molecular and cellular levels. Multimodality molecular imaging, which combines the advantages of various imaging modalities, provides even more comprehensive therapeutic efficacy assessment in preclinical and clinical studies. This review provides an overview of molecular imaging evaluation of therapeutic efficacy of the anti-tumor drugs in hepatocellular carcinoma (HCC) both in preclinical and clinical research, which holds great promise in guiding HCC treatment into the era of precision medicine.

Original languageEnglish
Pages (from-to)1455-1468
Number of pages14
JournalMolecular Imaging and Biology
Volume22
Issue number6
DOIs
StatePublished - Dec 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical trial
  • Hepatocellular carcinoma
  • Molecular imaging
  • Preclinical drug evaluation
  • Therapeutics

Fingerprint

Dive into the research topics of 'Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma'. Together they form a unique fingerprint.

Cite this